Orgenesis Appoints Leading Diabetes Expert, Camillo Ricordi, M.D., to Scientific Advisory Board
27 November 2012 - 2:00PM
Business Wire
Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a
development-stage company with a novel therapeutic technology
dedicated to converting a patient’s own liver cells into
functioning insulin-producing cells as a treatment for diabetes, is
pleased to announce the appointment of Camillo Ricordi, M.D., to
its Scientific Advisory Board.
Considered one of the world’s leading experts in cell
transplantation, Dr. Ricordi is the Stacy Joy Goodman Professor of
Surgery, Distinguished Professor of Medicine, Professor of
Biomedical Engineering, and Microbiology and Immunology at the
University of Miami Diabetes Research Institute. He also serves as
Director of the Diabetes Research Institute Cell Transplant Center
and Responsible Head of the NIH-funded cGMP Human Cell Processing
Facility.
Among his many accomplishments, Dr. Ricordi developed the
automated method for islet cell isolation called the "Ricordi
Method”. He has served as President of the Cell Transplant Society,
Co-founder and Chairman of the National Diabetes Research
Coalition, Co-founder and President of the International
Association for Pancreas and Islet Transplantation and a member of
the council of the Transplantation Society. Dr. Ricordi has
authored over 600 scientific publications and has been awarded 11
patents as an inventor. Dr. Ricordi completed his graduate and
post-graduate studies at the University of Milan, Italy.
Dr. Ricordi currently serves as Co-Editor in Chief of Cell
Transplantation.
“At the Diabetes Research Institute we are fully committed to
developing a biological cure for diabetes in the fastest and most
efficient way possible, helping scientists and their promising
projects worldwide with the highest collaborative spirit. I am glad
to be able to assist Orgenesis to further develop, assess and
verify the potential of their promising technology. If successful,
the proposed strategy may answer the longstanding call for a
solution to restore normal insulin production in people with
diabetes," commented Dr. Ricordi. “Accordingly, I am very pleased
to be joining the Orgenesis Scientific Advisory Board and look
forward to contributing to their efforts to advance this
potentially breakthrough treatment.”
“We are honored to have Dr. Ricordi join our Scientific Advisory
Board,” said Orgenesis CEO, Jacob BenArie. “Dr. Ricordi brings a
tremendous amount of clinical and scientific expertise and we know
that his guidance will prove invaluable to Orgenesis.”
About Orgenesis Inc.
Orgenesis (OTCBB: ORGS) is a development stage company with a
novel therapeutic technology that employs a molecular and cellular
approach directed at converting a patient's own liver cells into
functional insulin producing cells, as a treatment for diabetes.
The Company believes that converting the diabetic patient's own
tissue into insulin-producing cells overcomes the problem of donor
shortage and removes the risk of transplant rejection. If
successful, this could mean the end of diabetes, as we now know it.
For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which
are not purely historical. Such forward-looking statements include,
among other things, the expectations of management that our
regeneration technology can be developed as therapeutic treatment
for diabetes, and that its success will be a breakthrough towards
the end of diabetes as we know it. No assurance can be given that
any of the events anticipated by the forward-looking statements
will occur or, if they do occur, what benefits the Company will
obtain from them. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the inherent uncertainties
associated with new projects and development stage companies, which
include, without limitation, the potential failure of development
candidates to advance through preclinical studies or demonstrate
safety and efficacy in clinical testing and the ability to pass
clinical trials so as to move on to the next phase, our ability to
retain key employees and our ability to finance development or
satisfy the rigorous regulatory requirements for new medical
procedures. Competitors may develop better or cheaper alternatives
to our products. These forward-looking statements are made as of
the date of this news release, and we assume no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements. Investors should refer to the risk
factors disclosure outlined in our periodic reports filed from
time-to-time with the Securities and Exchange Commission.
On Behalf of the BoardOrgenesis Inc.
Vered Caplan, Chairperson
Orgenesis (QX) (USOTC:ORGS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Orgenesis (QX) (USOTC:ORGS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
